MTD 214
Alternative Names: MTD-214Latest Information Update: 28 Jul 2024
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Transplant rejection
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Transplant-rejection in United Kingdom (Parenteral, Controlled release)
- 14 Sep 2020 MTD 214 is available for licensing as of 14 Sep 2020. http://www.midatechpharma.com/
- 30 Jun 2020 Midatech has patent protection for Q-Sphera™ microsphere technology before June 2020